This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mann, A. P. Articles by Mehta, K. Search for Related Content PubMed PubMed Citation Articles by Mann, A. P. Articles by Mehta, K.

Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-B in Cancer Cells: Delineation of a Novel Pathway

Departments of ¹ Experimental Therapeutics, ² Molecular and Cellular Oncology, and ³ Pathology, The University of Texas M.D. Anderson Cancer Center; ⁴ Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas

Requests for reprints: Kapil Mehta, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Unit 362, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-8140; Fax: 713-745-4167; E-mail: kmehta{at}mdanderson.org.

The transcription factor nuclear factor-B (NF-B) plays an important role in regulating cell growth, apoptosis, and metastatic functions. Constitutive activation of NF-B has been observed in various cancers; however, molecular mechanisms resulting in such activation remain elusive. Based on our previous results showing that drug-resistant and metastatic cancer cells have high levels of tissue transglutaminase (TG2) expression and that this expression can confer chemoresistance to certain types of cancer cells, we hypothesized that TG2 contributes to constitutive activation of NF-B. Numerous lines of evidence showed that overexpression of TG2 is linked with constitutive activation of NF-B. Tumor cells with overexpression of TG2 exhibited increased levels of constitutively active NF-B. Activation of TG2 led to activation of NF-B; conversely, inhibition of TG2 activity inhibited activation of NF-B. Similarly, ectopic expression of TG2 caused activation of NF-B, and inhibition of expression of TG2 by small interfering RNA abolished the activation of NF-B. Our results further indicated that constitutive NF-B reporter activity in pancreatic cancer cells is not affected by dominant-negative IB. Additionally, coimmunoprecipitation and confocal microscopy showed that IB is physically associated with TG2. Lastly, immunohistochemical analysis of pancreatic ductal carcinoma samples obtained from 61 patients further supported a strong correlation between TG2 expression and NF-B activation/overexpression (P = 0.0098, Fisher's exact test). We conclude that TG2 induces constitutive activation of NF-B in tumor cells via a novel pathway that is most likely independent of IB kinase. Therefore, TG2 may be an attractive alternate target for inhibiting constitutive NF-B activation and rendering cancer cells sensitive to anticancer therapies. (Cancer Res 2006; 66(17): 8788-95)

This article has been cited by other articles:

				D. Telci, R. J. Collighan, H. Basaga, and M. Griffin Increased TG2 Expression Can Result in Induction of Transforming Growth Factor {beta}1, Causing Increased Synthesis and Deposition of Matrix Proteins, Which Can Be Regulated by Nitric Oxide J. Biol. Chem., October 23, 2009; 284(43): 29547 - 29558. [Abstract] [Full Text] [PDF]

				M. A. Antonyak, B. Li, A. D. Regan, Q. Feng, S. S. Dusaban, and R. A. Cerione Tissue Transglutaminase Is an Essential Participant in the Epidermal Growth Factor-stimulated Signaling Pathway Leading to Cancer Cell Migration and Invasion J. Biol. Chem., July 3, 2009; 284(27): 17914 - 17925. [Abstract] [Full Text] [PDF]

				M. Satpathy, M. Shao, R. Emerson, D. B. Donner, and D. Matei Tissue Transglutaminase Regulates Matrix Metalloproteinase-2 in Ovarian Cancer by Modulating cAMP-response Element-binding Protein Activity J. Biol. Chem., June 5, 2009; 284(23): 15390 - 15399. [Abstract] [Full Text] [PDF]

				M Mimeault and S K Batra Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer Gut, October 1, 2008; 57(10): 1456 - 1468. [Abstract] [Full Text] [PDF]

				G Feldmann, N Habbe, S Dhara, S Bisht, H Alvarez, V Fendrich, R Beaty, M Mullendore, C Karikari, N Bardeesy, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer Gut, October 1, 2008; 57(10): 1420 - 1430. [Abstract] [Full Text] [PDF]

				L. Cao, D. N. Petrusca, M. Satpathy, H. Nakshatri, I. Petrache, and D. Matei Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling Carcinogenesis, October 1, 2008; 29(10): 1893 - 1900. [Abstract] [Full Text] [PDF]

				J. Y. Hwang, L. S. Mangala, J. Y. Fok, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, D. J. Fiterman, P. E. Vivas-Mejia, M. T. Deavers, et al. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma Cancer Res., July 15, 2008; 68(14): 5849 - 5858. [Abstract] [Full Text] [PDF]

				A. Verma, S. Guha, P. Diagaradjane, A. B. Kunnumakkara, A. M. Sanguino, G. Lopez-Berestein, A. K. Sood, B. B. Aggarwal, S. Krishnan, J. G. Gelovani, et al. Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2476 - 2483. [Abstract] [Full Text] [PDF]

				A. Verma, S. Guha, H. Wang, J. Y. Fok, D. Koul, J. Abbruzzese, and K. Mehta Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells Clin. Cancer Res., April 1, 2008; 14(7): 1997 - 2005. [Abstract] [Full Text] [PDF]

				L. Ai, W.-J. Kim, B. Demircan, L. M. Dyer, K. J. Bray, R. R. Skehan, N. A. Massoll, and K. D. Brown The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer Carcinogenesis, March 1, 2008; 29(3): 510 - 518. [Abstract] [Full Text] [PDF]

				L. Falasca, M. G. Farrace, A. Rinaldi, L. Tuosto, G. Melino, and M. Piacentini Transglutaminase Type II Is Involved in the Pathogenesis of Endotoxic Shock J. Immunol., February 15, 2008; 180(4): 2616 - 2624. [Abstract] [Full Text] [PDF]

				G. Sethi, B. Sung, and B. B. Aggarwal Nuclear Factor-{kappa}B Activation: From Bench to Bedside Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31. [Abstract] [Full Text] [PDF]

				T.-S. Lai, Y. Liu, W. Li, and C. S. Greenberg Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells FASEB J, December 1, 2007; 21(14): 4131 - 4143. [Abstract] [Full Text] [PDF]

				M. Satpathy, L. Cao, R. Pincheira, R. Emerson, R. Bigsby, H. Nakshatri, and D. Matei Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase Cancer Res., August 1, 2007; 67(15): 7194 - 7202. [Abstract] [Full Text] [PDF]

				U. Akar, B. Ozpolat, K. Mehta, J. Fok, Y. Kondo, and G. Lopez-Berestein Tissue Transglutaminase Inhibits Autophagy in Pancreatic Cancer Cells Mol. Cancer Res., March 1, 2007; 5(3): 241 - 249. [Abstract] [Full Text] [PDF]